Recurrent Miscarriage

724 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Miscarriage and Bleeding in Early Pregnancy written for patients

Recurrent miscarriage is defined as the loss of three or more consecutive pregnancies.

Miscarriage, the most common complication of pregnancy, is the spontaneous loss of a pregnancy before the fetus has reached viability at 24 weeks of gestation. (20 weeks of gestation is taken in some parts of the world.)

  • Miscarriage occurs in 12-24% of recognised pregnancies.
  • 1% of couples trying to conceive have recurrent miscarriages.
  • This is much higher than the 0.34% calculated risk of three occurring consecutively by chance alone.
  • Following three consecutive miscarriages, the risk of further miscarriage is about 40%.
  • A woman may develop recurrent miscarriage after a successful pregnancy.

No underlying cause is found in many women who experience recurrent miscarriage.

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »

Risk factors

  • Increasing maternal age affects ovarian function and increases rates of aneuploidy in association with older oocytes.
  • As the number of miscarriages increases, the likelihood of chromosomal abnormalities as the cause decreases and the risk of an underlying maternal cause increases.

Genetic abnormalities

  • Recurrent miscarriage may be linked to chromosomal abnormality in 2-5% of couples.
  • A balanced reciprocal or Robertsonian translocation is the most common type[2].

Antiphospholipid syndrome (APS)

  • This is the most important treatable cause of recurrent miscarriage.
  • The antiphospholipid antibodies, lupus anticoagulant, anticardiolipin antibodies and anti-B2-glycoprotein I antibodies may be associated with recurrent miscarriage before ten weeks.
  • Antiphospholipid antibodies are present in 15% of women with recurrent miscarriage.
  • APS is the only proven thrombophilia that is associated with adverse pregnancy outcomes[3].

Structural[4]

  • Uterine anomalies (arcuate or septate) are seen in between 10-25% of cases of recurrent miscarriage, particularly second-trimester miscarriages. Only 50% of pregnancies where there is a uterine structural abnormality achieve term delivery.
  • Multiple intramural and submucosal fibroids are associated with an increased risk of miscarriage but whether myomectomy improves the live birth rate is unclear.
  • Cervical incompetence (late miscarriage preceded by spontaneous rupture of membranes or painless cervical dilatation) may often be a cause of mid-trimester recurrent miscarriage.

Endocrine

  • Women with polycystic ovary syndrome are at higher risk of miscarriage, which may be related to insulin resistance and hyperinsulinaemia.
  • There is insufficient evidence to support the use of metformin during pregnancy to reduce this risk.
  • Uncontrolled diabetes mellitus is a risk factor for recurrent miscarriage.

Immune

  • Women with recurrent miscarriage have more natural killer cells in their uterine mucosa than controls and those with the highest levels have a correspondingly high rate of miscarriage in subsequent pregnancies.
  • However, there is no association between the levels of natural killer cells in peripheral blood and the levels in the uterine mucosa. Levels of natural killer cells in peripheral blood are not predictive of pregnancy outcome in women with unexplained recurrent miscarriage.

Inherited thrombophilia

  • Inherited thrombophilia, such as protein C and protein S deficiency, may have a role in recurrent miscarriage, because of an increased risk of thrombosis in the uteroplacental circulation, although the evidence for a causal effect is weak[5]. The relationship appears to be strongest for late pregnancy loss as opposed to miscarriage.
  • Women with second-trimester miscarriage should be screened for inherited thrombophilia.

Infections
Bacterial vaginosis in the first trimester is a risk factor for second-trimester miscarriage and preterm delivery[6].

  • Antiphospholipid and B2-glycoprotein I antibodies:
    • The presence of these is associated with early miscarriages and maternal morbidity and is referred to as primary APS. There is requirement for two tests at least six weeks apart showing either lupus anticoagulant or anticardiolipin antibodies at significant levels.
    • Women with recurrent first-trimester miscarriage and all women with one or more second-trimester miscarriages should be screened for antiphospholipid antibodies before pregnancy.
  • Women with second-trimester miscarriage should be screened for inherited thrombophilias including factor V Leiden, factor II (prothrombin) gene mutation and protein S.
  • All women with recurrent first-trimester miscarriage and all women with one or more second-trimester miscarriages should have pelvic ultrasound to assess uterine anatomy. 
  • Women who have had one or more second-trimester miscarriages and suspected cervical weakness may be offered serial cervical sonographic surveillance.
  • If uterine anomalies are detected then further investigations, such as hysteroscopy and/or laparoscopy, may be required.

Karyotyping

  • Karyotyping of products of conception should be undertaken on the products of conception from the third (and any subsequent) miscarriages. If an unbalanced structural chromosomal abnormality is found, referral to genetics is indicated[1].
  • Parental peripheral blood karyotyping of both partners should be performed in couples with recurrent miscarriage where testing of products of conception reports an unbalanced structural chromosomal abnormality.

NB: the Royal College of Obstetricians and Gynaecologists (RCOG) does not recommend routine screening for diabetes, inherited coagulopathies, thyroid disease, serum prolactin, or TORCH syndrome (toxoplasmosis, other, rubella, cytomegalovirus, herpes simplex)[1].

General advice[4]

Reassurance should be given about the high probability of a successful outcome. In a large trial that included women with 4.2 consecutive miscarriages and an average age of 32.7 years, the placebo group was shown to have a live birth rate of 65%. There is a suggestion that the reassurance gained from frequent antenatal visits and ultrasound examinations may improve outcomes.

Pharmacological treatment

Heparin

  • In primary APS patients, heparin combined with low-dose aspirin improves live birth rate to 70% from reported rates in untreated women with APS of as low as 10%[7].
  • A systematic review and meta-analysis has shown no reduction in the risk of miscarriage in women with inherited thrombophilia treated with low molecular weight heparin (LMWH)[5]

Metformin

  • There is some evidence suggesting that use of metformin during pregnancy is associated with a reduction in the miscarriage rate in women with polycystic ovary syndrome[8]. However, the data are contradictory and a systematic review and meta-analysis found no effect on the miscarriage risk[9].
  • The  RCOG does not recommend its use in pregnancy at present, until further randomised prospective study results are available to provide adequate evidence of safety and efficacy of its use.

Progesterone

  • The progesterone in recurrent miscarriage (PROMISE) study, a large randomised, double-blind, placebo-controlled multicentre trial, has shown[10]:
    • No benefit from progesterone supplementation in women with unexplained recurrent miscarriages.
    • No sign that progesterone delays the time of miscarriage.
    • Over 60% of the women who conceived within a year of inclusion in the study, all of whom had a history of recurrent miscarriage, had a live birth, whether they had progesterone treatment or placebo.

Human chorionic gonadotrophin (hCG) hormone
The evidence supporting hCG supplementation to prevent recurrent miscarriage is equivocal; higher-quality evidence shows no benefit[11].

Immunotherapy
Paternal cell immunisation, third-party donor leukocytes, trophoblast membranes, and intravenous immunoglobulin have all been used to treat women with otherwise unexplained miscarriage. None has shown any significant benefit over placebo in improving the live birth rate[12].

Surgical treatment[13]

  • Cervical cerclage (a Shirodkar or McDonald suture) is a prophylactic measure inserted around 12-14 weeks, when cervical incompetence is suspected. However, cervical incompetence may be overdiagnosed as a cause of second-trimester miscarriage. The cerclage procedure also carries a risk of stimulating uterine contractions.
  • In women with a history of one second-trimester miscarriage attributable to cervical factors and a singleton pregnancy, a cerclage should be offered if a cervical length of ≥25 mm is detected by transvaginal scan before 24 weeks of gestation[1].
  • In the USA, 1 in 300 women receive a cerclage but the rate is over 1% in many other populations.
  • Preconceptual abdominal cerclage is increasingly used; there is no evidence that it has any detrimental effects but evidence of benefit is still lacking.

Further reading & references

  • Jeve YB, Davies W; Evidence-based management of recurrent miscarriages. J Hum Reprod Sci. 2014 Jul;7(3):159-69. doi: 10.4103/0974-1208.142475.
  1. Recurrent Miscarriage, Investigation and Treatment of Couples; Royal College of Obstetricians and Gynaecologists (May 2011)
  2. Rai R, Regan L; Recurrent miscarriage. Lancet. 2006 Aug 12;368(9535):601-11.
  3. McNamee K, Dawood F, Farquharson R; Recurrent miscarriage and thrombophilia: an update. Curr Opin Obstet Gynecol. 2012 Aug;24(4):229-34. doi: 10.1097/GCO.0b013e32835585dc.
  4. Branch DW, Gibson M, Silver RM; Clinical practice. Recurrent miscarriage. N Engl J Med. 2010 Oct 28;363(18):1740-7.
  5. Skeith L, Carrier M, Kaaja R, et al; A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. Blood. 2016 Mar 31;127(13):1650-5. doi: 10.1182/blood-2015-12-626739. Epub 2016 Feb 2.
  6. Bacterial vaginosis; NICE CKS, July 2014 (UK access only)
  7. Ziakas PD, Pavlou M, Voulgarelis M; Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010 Jun;115(6):1256-62.
  8. De Leo V, Musacchio MC, Piomboni P, et al; The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):63-6. Epub 2011 May 6.
  9. Palomba S, Falbo A, Orio F Jr, et al; Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2009 Nov;92(5):1646-58. doi: 10.1016/j.fertnstert.2008.08.087. Epub 2008 Oct 19.
  10. Coomarasamy A, Williams H, Truchanowicz E, et al; A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med. 2015 Nov 26;373(22):2141-8. doi: 10.1056/NEJMoa1504927.
  11. Morley LC, Simpson N, Tang T; Human chorionic gonadotrophin (hCG) for preventing miscarriage. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD008611. doi: 10.1002/14651858.CD008611.pub2.
  12. Wong LF, Porter TF, Scott JR; Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev. 2014 Oct 21;(10):CD000112. doi: 10.1002/14651858.CD000112.pub3.
  13. Abbott D, To M, Shennan A; Cervical cerclage: a review of current evidence. Aust N Z J Obstet Gynaecol. 2012 Jun;52(3):220-3. doi: 10.1111/j.1479-828X.2012.01412.x. Epub 2012 Feb 15.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but makes no warranty as to its accuracy. Consult a doctor or other healthcare professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Hayley Willacy
Current Version:
Peer Reviewer:
Miss Shalini Patni
Document ID:
2707 (v24)
Last Checked:
30/11/2016
Next Review:
29/11/2021

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

 
 
Patient Access app - find out more Patient facebook page - Like our page